Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolPHATnews
Exchange: NASDAQ·Updated 04:19 AM EST

PHAT News

News
all
press releases
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity
Phathom said BDR Pharmaceuticals International Pvt. Ltd. filed suit in the U.S. District Court for the District of Columbia against the FDA and related federal defendants.
Stocktwits
Phathom Says BDR Pharmaceuticals Sues FDA Over VOQUEZNA Exclusivity
(RTTNews) - Biopharmaceutical company Phathom Pharmaceuticals, Inc. (PHAT) announced on Friday that Mumbai, India-based BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the U.S. Food and Drug Administration or FDA, challenging the agency's decision to grant...
Nasdaq News: Markets
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) for violations of the securities laws. INVESTIGATION DETAILS: The...
Business Wire
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI).
Stocktwits
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million$325 million from its previously issued $320 million$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If...
Business Wire
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PR Newswire NEW YORK, July 31, 2026 Phathom...
PR Newswire
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.
Stocktwits
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) PR Newswire...
PR Newswire
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.